Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia

Pediatric Blood & Cancer
Michael R JengWinfred C Wiang


Immunosuppressive therapy (IS) is effective in the treatment of patients with acquired severe aplastic anemia (SAA). An enhanced myeloid response and decreased infection risk may be possible with the addition of a hematopoietic cytokine. Published data on the combination of cytokines and IS in patients with SAA are limited. The addition of G-CSF to IS shortens the time to neutrophil count recovery, but may not improve overall survival. Because GM-CSF acts differently than G-CSF, its use in combination with IS may be different. A retrospective chart review was performed on patients diagnosed with SAA and treated with IS and GM-CSF at St. Jude Children's Research Hospital. Hematologic recovery, prognostic factors, and infection data were collected. Eighteen patients were included in this study. The median age at diagnosis was 7.2 years (range 1.8-17.0). Ten patients (56%) had a complete response, four (22%) a partial response, and four (22%) no response. Median time to erythrocyte and platelet transfusion independence were 90 (18,243) and 64 days (18-243), and to discontinuation of treatment 287 days (90-730). Median time to partial (ANC > 500) and full (ANC > 1,500) neutrophil recovery were 41 and 51 days, respectively. Seventee...Continue Reading


Sep 27, 1990·The New England Journal of Medicine·S KojimaT Matsuyama
Mar 1, 1991·American Journal of Clinical Pathology·S FalkK Hübner
Nov 23, 1989·The New England Journal of Medicine·J E GroopmanD T Scadden
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·L M Aledort, D M Dimichele
Feb 17, 2000·Seminars in Hematology·J F TisdaleJ Maciejewski
Nov 26, 2002·Hematology·Alan D D'AndreaAkiko Shimamura
Dec 11, 2002·British Journal of Haematology·Eliane GluckmanEuropean Group for Blood and Marrow Transplantation Working Party for Severe Aplastic Anemia
Mar 8, 2003·JAMA : the Journal of the American Medical Association·Stephen RosenfeldNeal S Young
Jul 2, 2003·Cancer·Harrys A TorresDimitrios P Kontoyiannis
Jul 23, 2003·Neurology·Heather J FullertonS Claiborne Johnston


Apr 9, 2008·Current Opinion in Hematology·Neal S YoungRodrigo T Calado
Jun 17, 2006·Blood·Neal S YoungPhillip Scheinberg
Jun 1, 2012·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Liren QianJianming Cai
Oct 18, 2007·Pediatric Blood & Cancer·Bunchoo PongtanakulYigal Dror
May 1, 2013·Pediatric Hematology and Oncology·Deniz Yilmaz KarapinarKaan Kavakli
Aug 26, 2016·Human Vaccines & Immunotherapeutics·Ting-Wei YuJiantai Timothy Qiu
Aug 9, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hrishikesh M MehtaSeth J Corey

Related Concepts

Hypoplastic Anemia
Immunosuppressive Agents
Opportunistic Infections
Retrospective Studies
Granulocyte-Macrophage Colony-Stimulating Factor

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Wiadomości lekarskie : organ Polskiego Towarzystwa Lekarskiego
Mariola Osińska-KrólakAnna Balcar-Boroń
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
H H Gerhartz
© 2021 Meta ULC. All rights reserved